Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Nov 07, 2021 1:08pm
91 Views
Post# 34097511

RE:RE:Nov 11 - release its third quarter 2021 financial results

RE:RE:Nov 11 - release its third quarter 2021 financial results
Snowballgrowth wrote:
MrMugsy wrote:

MONTREAL, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2021 financial results on Thursday, November 11, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.

Date: Thursday, November 11, 2021

Time: 8:30 a.m. ET

Telephone: Toll Free: 866-269-4264 or International 1-647-792-1240

Webcastwww.gud-knight.com or Webcast
This is a listen-only audio webcast. Media Player is required to listen to the broadcast.



Some sales growth and better margins could be great. Expectations are very low at current stock price. 



Yes - heading into the best potential for efficency gain with the different business units at GUD.  Also ... could be at a low point for currencies going forward - watching closely (future).

but - most importantly - will be when  investors/investment houses decide GUD needs to be added as a core holding.  That's really what we're waiting for if you're interested in share price appreciation (IMO).

That's the "show me" part of the business - convincing investment houses that GUD is on that operational growth curve and should be a core holding.  That rush into GUD is the point that demand begins to outpace supply.  No way I'd bet on a date for that - though.

at some point !
<< Previous
Bullboard Posts
Next >>